Clinical Trials
26 trialsiCCaRE
University of Ilorin Teaching Hospital
CaBRA
Gustave Roussy, Cancer Campus, Grand Paris
SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
CSPC Megalith Biopharmaceutical Co.,Ltd.
ADVANCED-3
Protara Therapeutics
RESCUE
Relmada Therapeutics, Inc.
Lu-177 PSMA Treatment in Cell Renal Carcinoma
Ankara University
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
SWOG Cancer Research Network
Chrono-EVP
British Columbia Cancer Agency
The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
British Columbia Cancer Agency
REINFORCE
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer
Thomas Jefferson University
TRAIN
The Christie NHS Foundation Trust
HERO
Fudan University
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Alliance for Clinical Trials in Oncology
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
Peking University Cancer Hospital & Institute
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
Yunhe Pharmaceutical (Tianjin) Co., Ltd
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
Yunhe Pharmaceutical (Tianjin) Co., Ltd
PCS-XII
Charles LeMoyne Hospital
A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
Qilu Pharmaceutical Co., Ltd.
mCRPC
Fudan University
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
First Affiliated Hospital, Sun Yat-Sen University
MINERVA
Medical University of Vienna
ESTABLISH
General University Hospital, Prague